Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02265744 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 730
- Enrollment target
NCT02265744 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 730 participants.
The verdict
NCT02265744, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 730 participants
- Enrollment target
Study Summary
Study evaluating the safety and efficacy of a novel biologic in the treatment of systemic lupus erythematosus in male and female adults. Patients who qualify will be randomized to either active BMS-931699 or placebo for initially, up to 24 weeks. Patients who complete the initial 24 weeks of treatment and who are responding to therapy will have the option to continue receiving BMS-931699 as part of a long-term extension (LTE). Disease activity and safety will be assessed over the course of the study through laboratory values, various rating scales accepted in systemic lupus erythematosus studies and patient self reporting.
Interventions
- DRUG BMS-931699
- DRUG Placebo matching BMS-931699
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 730 participants |
| Start Date | 2014-11-13 |
| Est. Completion | 2017-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02265744
The ClinicalTrials.gov registry entry for NCT02265744 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 730 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-931699 is the first listed.
NCT02265744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02265744 about?
NCT02265744 is a clinical study titled "Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus". Study evaluating the safety and efficacy of a novel biologic in the treatment of systemic lupus erythematosus in male and female adults. Patients who qualify will be randomized to either active BMS-931699 or placebo for initially, up to 24 weeks. Patients who complete the initial 24 weeks of treatme...
What is the current status of trial NCT02265744?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 730 participants. The study started on 2014-11-13. Estimated completion is 2017-11-30.
What interventions are being tested in trial NCT02265744?
The interventions under investigation include: BMS-931699 (DRUG), Placebo matching BMS-931699 (DRUG).
Who is sponsoring clinical trial NCT02265744?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.